Comprehensive Solutions for STI Testing

STIs demand our attention1

Every year, U.S. healthcare providers confront 3.6 million new cases of chlamydia and gonorrhea. This case volume is further complicated by the fact that many STIs present similar symptoms but require different treatments. This diagnostic challenge poses a serious threat to women’s health: upper genital tract infections, infertility, chronic pelvic pain, cervical cancer, and chronic infection with hepatitis viruses and HIV are just a few of the long-term implications of an untreated or persistent STI.2

Estimated prevalence of STIs in the United States (2013)1
Not to scale.

Better testing protects individuals and communities

  • Along with increased risk of serious complications, asymptomatic STIs increase the potential for sustained transmission in the community. Screening is a crucial measure for public as well as individual health.3
  • Because STI incidence is highest among adolescents and young adults, screening efforts focus on women between the age of 15-24 and identify as being sexually active.4
  • The CDC recommends NAAT as the preferred method for accurate screening of patients.5,6,7

Hologic’s Offerings

Our broad array of highly sensitive NAATs lead the market in accurate detection of pathogens that are associated with STIs including chlamydia, gonorrhea, trichomoniasis, mycoplasma genitalium and herpes simplex virus.

Aptima Combo 2® CT/NG Test

Aptima® Trichomonas Vaginalis Test

Aptima® Mycoplasma Genitalium Test

Aptima® HSV 1 & 2 Test

Contact Us

We are here to support you. Have a question or need to talk to a Hologic team member?